GNTI-122

Phase 1Biologic

GGentiBio, Inc

GNTI-122 is one of 2 biologic programs targeting Type 1 Diabetes (T1D). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 Diabetes (T1D)Recruiting

Type 1 Diabetes (T1D)Phase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Type 1 Diabetes (T1D)

#DrugCompanyPhaseTrials

Simponi

Johnson & Johnson

Phase 2

1 2

GNTI-122

GGentiBio, Inc

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Type 1 Diabetes (T1D)

NCT06919354

Clinical

Trials by Indication[1]

Type 1 Diabetes (T1D)1 trial

POLARIS: A Phase 1, Single Dose, Open-label Study of GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes (T1D)

Recruiting·GGentiBio, Inc·Phase 1·NCT06919354·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GNTI-122. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GNTI-122 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GNTI-122. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GentiBio, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: GGentiBio, Inc

GNTI-122

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Type 1 Diabetes (T1D)1 trial

References

Drug Info

Quick Facts

Related News